SCHEMBL1703314

SCHEMBL1703314

Nc1n[nH]c2ccnc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 1.00
KIT P10721 11/20 0.76
FLT3 P36888 11/20 0.76
VHL P40337 1/20 0.65
CSF1R P07333 7/20 0.59
LCK P06239 6/20 0.59
FLT1 P17948 6/20 0.59
FLT4 P35916 6/20 0.59
LYN P07948 5/20 0.59
BLK P51451 5/20 0.59
SRC P12931 4/20 0.59
FYN P06241 3/20 0.59
NTRK1 P04629 2/20 0.59
ABL1 P00519 2/20 0.59
AURKB Q96GD4 4/20 0.59
PLK4 O00444 3/20 0.59
AURKA O14965 3/20 0.59
ROCK2 O75116 3/20 0.59
FGFR1 P11362 3/20 0.59
RPS6KB1 P23443 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237406 0.88 KDR (0.78) KDRKITFLT3CSF1RLCK
SCHEMBL1703112 0.88 KDR (0.83) KDRKITFLT3CSF1RLCK
SCHEMBL1703611 0.88 KDR (0.78) KDRKITFLT3CSF1RLCK
SCHEMBL1702904 0.87 KDR (0.79) KDRKITFLT3CSF1RLCK
SCHEMBL421753 0.86 KDR (1.00) KDRKITFLT3VHLCSF1R
SCHEMBL1702763 0.85 KDR (0.74) KDRKITFLT3CSF1RLCK
SCHEMBL1703065 0.85 KDR (1.00) KDRKITFLT3CSF1RLCK
SCHEMBL2240148 0.85 KDR (0.75) KDRKITFLT3CSF1RLCK
SCHEMBL1703080 0.84 KDR (0.74) KDRKITFLT3VHLCSF1R
SCHEMBL2237920 0.83 KDR (0.83) KDRKITFLT3CSF1RLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885FLT3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.